Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) recently granted equity awards to five newly hired employees under its inducement plan, continuing the use of stock-based compensation to attract talent …
Madrigal Grants Equity Awards to Five New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) granted equity awards to 20 newly hired employees under its inducement compensation plan, a move tied to ongoing workforce expansion as the company …
Madrigal Grants Equity Awards to 20 New Employees Under Inducement Plan Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is set to present at the Goldman Sachs Global Healthcare Conference this week as investors evaluate the commercial trajectory of Rezdiffra, the …
Madrigal Investors Focus on Rezdiffra Growth at Goldman Event Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) reported new clinical and real-world data suggesting its liver disease drug Rezdiffra may reduce both cardiovascular and liver-related risk markers in patients with …
Madrigal Highlights Rezdiffra Data as MASH Market Expands Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) granted equity awards to 15 newly hired employees as the biotechnology company continues expanding operations around its approved liver disease treatment Rezdiffra and …
Madrigal Expands Workforce With Equity Hiring Grants Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) granted equity inducement awards to 47 newly hired non-executive employees as the company expands operations following the commercial launch of its MASH treatment …
Madrigal Pharmaceuticals Issues Equity Awards to 47 New Hires Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) reported first-quarter Rezdiffra sales of $311.3 million, more than doubling from a year earlier as physician adoption accelerated for the company’s liver …
Madrigal Rezdiffra Sales More Than Double in First Quarter Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) licensed a clinical-stage gene-silencing therapy from Arrowhead Pharmaceuticals to expand its pipeline of treatments for metabolic dysfunction-associated steatohepatitis, or MASH, including patients with …
Madrigal Licenses Arrowhead Drug Candidate for MASH Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, before U.S. markets open and will host a webcast at …
Madrigal to Report Q1 2026 Results May 6, Host Webcast Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) recently granted equity inducement awards to 12 new non-executive employees on April 1, 2026, under its 2025 Inducement Plan.
Madrigal Grants Equity Awards to 12 New Employees Read More